All In Biotech

Drug Trial Radar · NCT02024646

Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2

Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 484 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

484

Actual

Start

Mar 2014

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Dec 31, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis. The key secondary objective is to evaluate the efficacy of brodalumab compared to placebo at week 16. The safety objective of this study is to evaluate the safety profile of brodalumab in subjects with psoriatic arthritis.

Conditions

  • Psoriatic Arthritis

Interventions

  • 210 mg brodalumabDrug

    210 mg brodalumab administered via subcutaneous injection.

  • 140 mg brodalumabDrug

    140 mg brodalumab administered via subcutaneous injection.

  • PlaceboDrug

    Placebo administered via subcutaneous injection until week 24.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16Time frame: Baseline and 16 Weeks

Locations

103 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Peoria, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Cypress, California

  • Research Site

    Hemet, California

  • Research Site

    Huntington Beach, California

  • Research Site

    La Jolla, California

  • Research Site

    Palm Desert, California

  • Research Site

    Palo Alto, California

  • Research Site

    Victorville, California

  • Research Site

    Sarasota, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Paducah, Kentucky

  • Research Site

    Baton Rouge, Louisiana

  • Research Site

    Wheaton, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Battle Creek, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Lansing, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Rochester, New York

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Tulsa, Oklahoma

  • Research Site

    Dallas, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Waco, Texas

  • Research Site

    Chesapeake, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Victoria, British Columbia, Canada

  • Research Site

    Winnipeg, Manitoba, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    St. John's, Newfoundland and Labrador, Canada

  • Research Site

    Waterloo, Ontario, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Trois-Rivières, Quebec, Canada

Showing 40 of 103 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.